Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
522 stopped studies mapped to Lymphoid Leukemia and descendants · 86% state a reason
Over the 522 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03494569 | Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell… | Phase 1 | suspended | Apr 11, 2018 | City of Hope Medical Center | Accrual goal | Enrollment / accrual |
| NCT04601584 | GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell… | Phase 1 / Phase 2 | terminated | Oct 26, 2020 | AO GENERIUM | The sponsor discontinued the development of the drug for reasons other than safety. | Safety / toxicity |
| NCT06421155 | Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia | N/A | suspended | May 20, 2024 | Case Comprehensive Cancer Center | Voluntary hold by PI | Other (stated, no rule matched) |
| NCT07313592 | Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients | — | suspended | Jan 2, 2026 | Washington University School of Medicine | Admin review | Other (stated, no rule matched) |
| NCT06680661 | ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis | Phase 2 | suspended | Nov 8, 2024 | Leland Metheny | insufficient funding | Funding |
| NCT06704152 | BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant… | Phase 1 / Phase 2 | terminated | Nov 25, 2024 | BlueSphere Bio, Inc | Company Decision | Sponsor / business decision |
| NCT05262673 | NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL | Phase 1 | terminated | Mar 2, 2022 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT05277753 | NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL | Phase 1 | terminated | Mar 14, 2022 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT02392572 | ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk… | Phase 1 / Phase 2 | terminated | Mar 19, 2015 | M.D. Anderson Cancer Center | \<75% participants | Other (stated, no rule matched) |
| NCT07556757 | A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic… | Phase 1 | terminated | Apr 29, 2026 | ImmunityBio, Inc. | Study was terminated prematurely by the Sponsor for reasons not related to the safety of study drug | Safety / toxicity |
| NCT06703216 | Pre-emptive Anakinra for Cytokine Event Reduction(PACER) | Phase 1 / Phase 2 | withdrawn | Nov 25, 2024 | Kevin McNerney | The trial has been stopped pending FDA approval of modifications to the trial protocol. | Other (stated, no rule matched) |
| NCT03488225 | Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute… | Phase 2 | terminated | Apr 4, 2018 | M.D. Anderson Cancer Center | the study was closed early due to competing trials | Other (stated, no rule matched) |
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of… | Phase 1 | suspended | May 17, 2022 | Washington University School of Medicine | Drugs/Equipment Unavailable | Other (stated, no rule matched) |
| NCT05400122 | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming… | Phase 1 | suspended | Jun 1, 2022 | David Wald | Drugs unavailable | Other (stated, no rule matched) |
| NCT05828589 | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | Phase 1 | terminated | Apr 25, 2023 | BeOne Medicines | This decision is due to a company business decision with strategy change on the BGB-21447… | Safety / toxicity |
| NCT05086315 | First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult… | Phase 1 / Phase 2 | terminated | Oct 20, 2021 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT06447987 | Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed… | Phase 1 | suspended | Jun 7, 2024 | City of Hope Medical Center | Pending Interim Analysis | Efficacy / futility |
| NCT01962636 | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for… | N/A | terminated | Oct 14, 2013 | Masonic Cancer Center, University of Minnesota | No longer a research question to answer. | Other (stated, no rule matched) |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity… | Phase 2 | terminated | Aug 11, 2017 | Fred Hutchinson Cancer Center | Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and… | Safety / toxicity |
| NCT07585734 | Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute… | Phase 1 / Phase 2 | withdrawn | May 14, 2026 | Institute of Hematology & Blood Diseases Hospital, China | drug-associated adverse reactions | Safety / toxicity |
| NCT03808610 | Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or… | Phase 1 / Phase 2 | terminated | Jan 17, 2019 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06570915 | Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy(T-ALL-2024) | Phase 2 | withdrawn | Aug 26, 2024 | Institute of Hematology & Blood Diseases Hospital, China | No eligeble patients | Other (stated, no rule matched) |
| NCT06662227 | Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors | Early Phase 1 | suspended | Oct 28, 2024 | Wondercel Biotech (ShenZhen) | Because the implementation of the new regulation policy by the Chinese authority | Other (stated, no rule matched) |
| NCT07498465 | A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After… | Phase 1 | withdrawn | Mar 27, 2026 | Children's Oncology Group | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT05268003 | A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and… | Phase 2 | terminated | Mar 7, 2022 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT03856216 | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma… | Phase 2 | terminated | Feb 27, 2019 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT02333162 | Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in… | Phase 1 | suspended | Jan 7, 2015 | University of Chicago | Enrollment on hold pending amendment | Enrollment / accrual |
| NCT03547115 | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell… | Phase 1 | terminated | Jun 6, 2018 | MEI Pharma, Inc. | Business reasons, not related to safety or efficacy results. | Safety / toxicity |
| NCT05909527 | A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute… | Phase 1 / Phase 2 | withdrawn | Jun 18, 2023 | Guangzhou Bio-gene Technology Co., Ltd | Due to corporate strategic adjustment. | Sponsor / business decision |
| NCT03514017 | Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia | Phase 2 | terminated | May 2, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Funding unavailable | Funding |
| NCT05170828 | Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | Phase 1 | withdrawn | Dec 28, 2021 | Ossium Health, Inc. | Change in Study Design | Other (stated, no rule matched) |
| NCT04817761 | SPARK-ALL: Calaspargase Pegol in Adults With ALL | Phase 2 / Phase 3 | terminated | Mar 26, 2021 | Institut de Recherches Internationales Servier | Sponsor decision | Sponsor / business decision |
| NCT03913559 | Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia | Phase 2 | terminated | Apr 12, 2019 | St. Jude Children's Research Hospital | Closed due to slow accrual | Enrollment / accrual |
| NCT05316116 | Siltuximab in Large Granular Lymphocytic Leukemia (LGLL) | Early Phase 1 | terminated | Apr 7, 2022 | H. Lee Moffitt Cancer Center and Research Institute | lack of efficacy/futility | Efficacy / futility |
| NCT04809467 | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in…(topMIND) | Phase 1 / Phase 2 | terminated | Mar 22, 2021 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT05181904 | Gastric Content Ultrasound Monitoring Prior to Extubation in Critically Ill Children(GastrExtub) | — | terminated | Jan 10, 2022 | Hospices Civils de Lyon | Patient enrollment difficulties | Enrollment / accrual |
| NCT04049383 | CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL(CAR-20/19-T) | Phase 1 | terminated | Aug 8, 2019 | Medical College of Wisconsin | Low accrual | Enrollment / accrual |
| NCT04163718 | TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL) | Phase 2 | terminated | Nov 15, 2019 | H. Lee Moffitt Cancer Center and Research Institute | Drug no longer available | Other (stated, no rule matched) |
| NCT03708003 | Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL | Phase 2 | terminated | Oct 16, 2018 | Swiss Cancer Institute | The board decision has been made to conclude the trial ahead of schedule. The primary endpoint has… | Funding |
| NCT04230304 | Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic… | Phase 2 | terminated | Jan 18, 2020 | Mayo Clinic | Slow accrual | Enrollment / accrual |
| NCT05317936 | Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic… | Phase 1 / Phase 2 | terminated | Apr 8, 2022 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03698552 | ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic… | Phase 1 / Phase 2 | terminated | Oct 9, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05464836 | Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent… | Phase 2 | terminated | Jul 19, 2022 | M.D. Anderson Cancer Center | The sponsor requested termination due to internal reprioritization of resources. | Other (stated, no rule matched) |
| NCT00776373 | Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive…(UPCC 25406) | Phase 1 / Phase 2 | terminated | Oct 21, 2008 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT04035434 | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory… | Phase 1 / Phase 2 | terminated | Jul 29, 2019 | CRISPR Therapeutics AG | Patients to be followed up in the CRSP-ONC-LTF study | Other (stated, no rule matched) |
| NCT04541017 | Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual… | Phase 1 / Phase 2 | terminated | Sep 9, 2020 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT04240704 | Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL | Phase 1 | terminated | Jan 27, 2020 | Novartis Pharmaceuticals | Business, strategic, and development considerations and not due to any safety concerns | Safety / toxicity |
| NCT03860844 | Isatuximab in Combination With Chemotherapy in Pediatric Patients With…(ISAKIDS) | Phase 2 | terminated | Mar 4, 2019 | Sanofi | Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due… | Safety / toxicity |
| NCT03564678 | Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab… | Phase 2 | terminated | Jun 21, 2018 | M.D. Anderson Cancer Center | PI Request. Slow accrual and lack of clinical interest | Enrollment / accrual |
| NCT06639958 | A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at… | N/A | suspended | Oct 15, 2024 | Children's Oncology Group | All potential pilot phase pts have been enrolled. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 hours agoSource updated Sep 28, 2026source: clinicaltrials